The Quantellect read.As of Nov 19, 2026, 3 active firms cover Lexicon Pharmaceuticals Inc: 3 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $3.10 to $8.00 (about 2.6x), a sign of real disagreement on valuation. The average target of $5.70 sits 229% above the current $1.73. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 2 to 3 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.06 next quarter toward $-0.21 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 active firms
Buy
Strong Buy00%
Buy3100%
Neutral00%
Sell00%
Strong Sell00%
Based on 3 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$5.70
+229.5% upside
Average target across 3 active firms as of Nov 19, 2026 vs $1.73 current
Highest Target$8.00
Average Target$5.70
Lowest Target$3.10
Detailed analyst forecasts for LXRX
Showing 1–3 of 3 named analysts shown · 3 active firms in the rating projection
As of Nov 19, 2026, 3 of 3 active firms rate LXRX a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
LXRX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.06
Range $-0.06 – $-0.06 · 3 analysts
Next period, 3 analysts expect Lexicon Pharmaceuticals Inc to earn $-0.06 a share (range $-0.06 – $-0.06), versus $0.00 a year earlier. Full-year consensus is $-0.16, growing to $-0.21 the year after.
REVENUE · NEXT QUARTER
$603.3K
Range $0 – $1.3M · 3 analysts · -97% YoY
Revenue is expected to reach $603.3K (range $0 – $1.3M), -97.1% year-over-year. Full-year consensus is $37.4M, rising to $17.9M next year.
Top analysts covering Lexicon Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on LXRX.
#1
Joseph Stringer
Needham · Rank #256
Neutral
No targeton LXRX
Overall win rate
36%
+ Follow
#2
Yasmeen Rahimi
Piper Sandler · Rank #339
Buy
$6.00+246.8% to target
Overall win rate
30%
+ Follow
#3
Joseph Pantginis
HC Wainwright & Co. · Rank #373
Buy
$6.00+246.8% to target
Overall win rate
34%
+ Follow
#4
Yigal Nochomovitz
Citigroup · Rank #381
Buy
$3.10+79.2% to target
Overall win rate
38%
+ Follow
#5
Roanna Ruiz
SVB Leerink · Rank #513
Neutral
$1.00-42.2% to target
Overall win rate
30%
+ Follow
LXRX stock forecast FAQ
What is LXRX's average 12-month price target?+
The 3 active firms with a live target average $5.70 for Lexicon Pharmaceuticals Inc over the next 12 months, ranging from a $8.00 high to a $3.10 low, as of Nov 19, 2026.
Is LXRX stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 3 active firms as of Nov 19, 2026, 3 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for LXRX?+
The Street-high target is $8.00 (Cantor Fitzgerald), and the Street-low is $3.10 (Citigroup). The average of all 3 active-firm targets is $5.70.
How many active Wall Street firms cover LXRX?+
3 active firms have a recognized rating on Lexicon Pharmaceuticals Inc as of Nov 19, 2026, and 3 active firms carry a live 12-month price target.
Who is the most accurate analyst covering LXRX?+
Among analysts who currently cover LXRX, Joseph Stringer of Needham has the strongest overall Quantellect track record (Rank #256). Their current call is Neutral.
What is Lexicon Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.06 per share (range $-0.06 – $-0.06) across 3 analysts. Full-year EPS is projected at $-0.16, rising to $-0.21 the following year.
How much revenue is Lexicon Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $603.3K (range $0 – $1.3M). Full-year revenue is projected at $37.4M, growing to $17.9M next year.
Have analysts been upgrading or downgrading LXRX lately?+
As of Nov 19, 2026, 3 of 3 active firms rate LXRX a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their LXRX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.